Biocodex Report issue

Contributed to NME For profit Phase 3 Phase 4
Founded: Gentilly France (1953)

Organization Overview

First Clinical Trial
1999
NCT00002088
First Marketed Drug
2018
stiripentol (diacomit)
First NDA Approval
2018
stiripentol (diacomit)
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Biocodex | BIOCODEX SA | Laboratoires Biocodex | Laboratoires Biocodex (Montrouge, France)

Indications

Approved Indications


 

Epilepsies, Myoclonic

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 2)

Diarrhea (Phase 3)

Gastroenteritis (Phase 4)

HIV Infections (Phase 2)

Hyperoxaluria, Primary (Phase 2)

Immunologic Deficiency Syndromes (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 8